Literature DB >> 6616493

Evidence of possible dose-dependent doxorubicin plasma kinetics in man.

R C Boston, D R Phillips.   

Abstract

The published plasma clearance profiles of doxorubicin in man (with differing liver status) have been analyzed further using a kinetic model instead of a linear regression model. At high (60 mg/m2 and 45 mg/m2) and intermediate (30 mg/m2) doxorubicin dose levels, a triphasic drug clearance pattern is apparent. However, at a low dose level (15 mg/m2), a biphasic profile can adequately describe the kinetics. This association of the kinetics with drug dose has been demonstrated in several ways, the simplest of which involves graphic overlaying of juxtaposed plasma clearances, and shows the emergence of a kinetic profile for low dose levels that is markedly different from that at high dose levels. At doses greater than about 45 mg/m2, a probable saturation of response mechanisms is observed. It is not possible to interpret these results in terms of pure dose-dependent responses because of the varying health status of the individual subjects between and within experimental treatment. However, in light of our findings further investigation into the possibility of such an effect should be undertaken, particularly in view of its clinical ramifications.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6616493

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  6 in total

1.  Flavone acetic acid: a nonlinear pharmacokinetic model.

Authors:  A Gouyette; D J Kerr; S B Kaye; A Setanoians; J Cassidy; C Bradley; G Forrest; M Soukop
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Pharmacokinetic study of i.v. infusions of adriamycin.

Authors:  S Eksborg; H S Strandler; F Edsmyr; I Näslund; P Tahvanainen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

4.  Pharmacokinetics of doxorubicin in man: dose and schedule dependence.

Authors:  R Erttmann; N Erb; A Steinhoff; G Landbeck
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

5.  Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver.

Authors:  F Ballet; P Vrignaud; J Robert; C Rey; R Poupon
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.

Authors:  C J Twelves; N A Dobbs; M Aldhous; P G Harper; R D Rubens; M A Richards
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.